In stock


2 mg per vial
Purchase this product now and earn 44 Points!

This product is prepared for LABORATORY RESEARCH USE ONLY and may not be used for other purposes.


Free & Fast




Molecular Formula C167H272N48047
Molecular Weight 3647.2
Monoisotopic Mass 3645.0154843
Polar Area 1540
Complexity 8580
XLogP -11.7
Heavy Atom Count 258
Hydrogen Bond Donor Count 54
Hydrogen Bond Acceptor Count 52
Rotatable Bond Count 128
Physical Appearance Fine White Lyophilized Powder
Stability Lyophilized protein is to be stored at -20°C. It is recommended to aliquot the reconstituted (dissolved) protein into several discrete vials in order to avoid repeated freezing and thawing. Reconstituted protein can be stored at 4°C
PubChem LCSS CJC-1295 WITH DAC Laboratory Chemical Safety Summary


CID 91971820
InChI InChI=1S/C165H269N47O46/c1-22-87(15)130(209-137(233)92(20)185-148(244)116(76-127(225)226)196-136(232)89(17)183-138(234)99(168)73-95-44-48-97(217)49-45-95)160(256)204-115(74-94-36-25-24-26-37-94)154(250)211-132(93(21)216)162(258)195-108(54-57-123(171)221)145(241)205-120(80-215)158(254)200-114(75-96-46-50-98(218)51-47-96)153(249)192-105(43-35-66-182-165(177)178)141(237)191-102(40-28-31-62-167)146(242)208-129(86(13)14)159(255)202-109(68-81(3)4)147(243)184-90(18)135(231)189-106(52-55-121(169)219)143(239)198-112(71-84(9)10)151(247)206-118(78-213)156(252)186-91(19)134(230)188-103(41-33-64-180-163(173)174)140(236)190-101(39-27-30-61-166)142(238)197-111(70-83(7)8)150(246)199-110(69-82(5)6)149(245)194-107(53-56-122(170)220)144(240)201-117(77-128(227)228)155(251)210-131(88(16)23-2)161(257)203-113(72-85(11)12)152(248)207-119(79-214)157(253)193-104(42-34-65-181-164(175)176)139(235)187-100(133(172)229)38-29-32-63-179-124(222)60-67-212-125(223)58-59-126(212)224/h24-26, 36-37, 44-51, 58-59, 81-93, 99-120, 129-132, 213-218H, 22-23, 27-35, 38-43, 52-57, 60-80, 166-168H2, 1-21H3, (H2, 169, 219)(H2, 170, 220)(H2, 171, 221)(H2, 172, 229)(H, 179, 222)(H, 183, 234)(H, 184, 243)(H, 185, 244)(H, 186, 252)(H, 187, 235)(H, 188, 230)(H, 189, 231)(H, 190, 236)(H, 191, 237)(H, 192, 249)(H, 193, 253)(H, 194, 245)(H, 195, 258)(H, 196, 232)(H, 197, 238)(H, 198, 239)(H, 199, 246)(H, 200, 254)(H, 201, 240)(H, 202, 255)(H, 203, 257)(H, 204, 256)(H, 205, 241)(H, 206, 247)(H, 207, 248)(H, 208, 242)(H, 209, 233)(H, 210, 251)(H, 211, 250)(H, 225, 226)(H, 227, 228)(H4, 173, 174, 180)(H4, 175, 176, 181)(H4, 177, 178, 182)/t87-, 88-, 89+, 90-, 91-, 92-, 93+, 99-, 100-, 101-, 102-, 103-, 104-, 105-, 106-, 107-, 108-, 109-, 110-, 111-, 112-, 113-, 114-, 115-, 116-, 117-, 118-, 119-, 120-, 129-, 130-, 131-, 132-/m0/s1
Isomeric SMILES CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCNC(=O)CCN3C(=O)C=CC3=O)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
IUPAC Name (3S)-4-[[(2S)-1-[[(2S, 3S)-1-[[(2S)-1-[[(2S, 3R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S, 3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-6-[3-(2, 5-dioxopyrrol-1-yl)propanoylamino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1, 5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1, 5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1, 5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid

2D Structure

Generated by Extreme Peptide with Open Babel, version 2.3.1, (accessed June 28, 2022)

CJC-1295 WITH DAC 2D molecular structure vector generated with oBabel


CJC-1295 DAC is a synthetic peptide developed to be an analogy of growth hormone releasing hormone (GHRH)1. The 29 amino acid sequence is derived from GRF(1-29), a naturally occurring growth hormone releasing factor.

CJC-1295 DAC is reported to be a potent agent for the stimulation of long-term growth hormone (GH) and IGF-1 release2. These biochemical actions have been shown to result in the promotion of lean body mass, enhanced strength, increased appetite, and an improved quality of sleep in animal test subjects3.

Product Comparison

Though CJC-1295 DAC is an analogy of GRF(1-29) and acts to release GH through a similar pathway, CJC-1295 DAC benefits from a much improved half-life relative to its native counterpart4. By existing in the bloodstream for long periods of time before degradation, CJC-1295 DAC is able to promote sustained GH release.

In spite of having a similar site of action, CJC-1295 DAC (and CJC-1295 no DAC) does not stimulate GH production using the same biochemical pathway as the popular GH secretagogue GHRP-65. In light of this observation, it has been possible for researchers to administrate CJC-1295 species and GHRP-6 concurrently in order to achieve an additive positive effect on GH release.

Drug Affinity Complex

The drug affinity complex (DAC) is a chemical group fixed to CJC-1295 that helps the peptide escape degradation by natural enzymes. By adding a component that gives CJC-1295 an affinity for albumin6, a naturally occurring protein in blood plasma, the peptide can achieve a much longer systemic half-life.

Preference for a long or short peptide half-life depends entirely on the research application of these agents.


CJC-1295 DAC; Sermonil; Sermonil-CJC-1295 DAC; Sermorelin Maleimidopropionyl; Modified GRF 1-29 with DAC

Peer-Reviewed Sources:

  1. Sackmann-Sala, L., Ding, J., Frohman, L. A., & Kopchick, J. J. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 19(6), 471-477. ↩︎
  2. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. ↩︎
  3. Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294. ↩︎
  4. Jette, L., Leger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., … & Bridon, D. P. (2005). Human growth hormone-releasing factor (hGRF) 1–29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: Identification of CJC-1295 as a long-lasting GRF analog. Endocrinology,146(7), 3052-3058. ↩︎
  5. Cordido, F., Penalva, A., Dieguez, C., & Casanueva, F. F. (1993). Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. The Journal of Clinical Endocrinology & Metabolism, 76(4), 819-823. ↩︎
  6. Beals, J. M., & Shanafelt, A. B. (2006). Enhancing exposure of protein therapeutics. Drug Discovery Today: Technologies, 3(1), 87-94. ↩︎

All literature, information, and data, provided on this website are for informational and educational purposes only.

Accurate research is our priority.

Same Day Shipping
We offer same day shipping on all orders of in stock items placed before 12:00pm EST.
Dedicated Service
Our team is readily available to assist with all of your customer service requests.
Free Shipping
We've got you covered! Free shipping is available on any order over $50.
Earn Rewards
Earn points every time you buy from us and use them towards future orders!
Extreme Peptide vial with logo and indicators